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CLINICAL PRACTICE GUIDE-lines are a powerful influ-ence on management strate-gies for common conditions.
When evidence that treating risk fac-
tors reduces disease and improves
health outcomes is provided by large
and well-conducted randomized con-
trolled trials, guidelines can appropri-
ately summarize the relevant data and
widely disseminate recommendations
for best practice. However, when prac-
tice guidelines promote therapeutic
strategies without sufficient evidence of
effectiveness or harms, overtreatment
and widespread inappropriate use of
medications, services, or devices may
occur. Accordingly, guidelines may rec-
ommend health interventions that do
not actually improve population out-
comes or the quality of care, unneces-
sarily increase health care expendi-
ture, and may even harm individuals
who might be expected to receive small
or negligible treatment benefit.
An important example is anemia in
chronic kidney disease. Guidelines1,2
For editorial comment see p 1138.
Context Clinical practice guidelines on the management of mineral and bone disor-
ders due to chronic kidney disease recommend specific treatment target levels for se-
rum phosphorus, parathyroid hormone, and calcium.
Objective To assess the quality of evidence for the association between levels of
serum phosphorus, parathyroid hormone, and calcium and risks of death, cardiovas-
cular mortality, and nonfatal cardiovascular events in individuals with chronic kidney
disease.
Data Sources The databases of MEDLINE (1948 to December 2010) and EMBASE
(1947 to December 2010) were searched without language restriction. Hand searches
also were conducted of the reference lists of primary studies, review articles, and clini-
cal guidelines along with full-text review of any citation that appeared relevant.
Study Selection Of 8380 citations identified in the original search, 47 cohort stud-
ies (N=327 644 patients) met the inclusion criteria.
Data Extraction The characteristics of study design, participants, exposures, and
covariates together with the outcomes of all-cause mortality, cardiovascular mortal-
ity, and nonfatal cardiovascular events at different levels of serum phosphorus, para-
thyroid hormone, and calcium were analyzed within studies. Data were summarized
across studies (when possible) using random-effects meta-regression.
Data Synthesis The risk of death increased 18% for every 1-mg/dL increase in se-
rum phosphorus (relative risk [RR], 1.18 [95% confidence interval {CI}, 1.12-1.25]). There
was no significant association between all-cause mortality and serum level of parathy-
roid hormone (RR per 100-pg/mL increase, 1.01 [95% CI, 1.00-1.02]) or serum level of
calcium (RR per 1-mg/dL increase, 1.08 [95% CI, 1.00-1.16]). Data for the association
between serum level of phosphorus, parathyroid hormone, and calcium and cardiovas-
cular death were each available in only 1 adequately adjusted cohort study. Lack of ad-
justment for confounding variables was not a major limitation of the available studies.
Conclusions The evidentiary basis for a strong, consistent, and independent associa-
tion between serum levels of calcium and parathyroid hormone and the risk of death and
cardiovascular events in chronic kidney disease is poor. There appears to be an associa-
tion between higher serum levels of phosphorus and mortality in this population.
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promoted anemia as a risk factor for
mortality based on observational evi-
dence of an association between low he-
moglobin levels and the risks of death
and hospitalization.3,4 It was argued that
anemia required treatment in individu-
als with chronic kidney disease, but ran-
domized controlled trials testing epo-
etins (an intervention that increases
hemoglobin) showed that targeting
higher hemoglobin levels caused
harm,5-7 indicating that existing guide-
lines (based on observational data) were
at best misleading.
A similar pattern has emerged in
guidelines relating to the manage-
ment of bone and mineral disorders in
individuals with chronic kidney dis-
ease. Chronic kidney disease causes
complicated changes in calcium and
phosphorus metabolism8 for which nu-
merous drugs including phosphorus
binders, vitamin D compounds, and cal-
cimimetic agents have been specifi-
cally developed and promoted. Ne-
phrology guidelines recommend targets
and treatment strategies to correct se-
rum levels of phosphorus, calcium, and
parathyroid hormone because obser-
vational data suggest there is an asso-
ciation between these potential risk bio-
markers and vascular disease and
death.9,10 However, to date, random-
ized controlled trials have not shown
that treating mineral levels with exist-
ing treatment options reduces cardio-
vascular events or mortality.11-13 Nearly
all such trials have been underpow-
ered for mortality and cardiovascular
outcomes, and a large comparative trial
of phosphorus binders in hemodialy-
sis found no evidence for benefit on
mortality.14 Existing guidelines (based
primarily on observational studies) may
be inappropriately promoting treat-
ment for abnormal mineral metabo-
lism in individuals with chronic kid-
ney disease.
Given the burden of cardiovascular
morbidity in individuals with chronic
kidney disease and the potential for se-
rum levels of phosphorus, parathy-
roid hormone, and calcium to act as im-
portant modifiable risk factors for
disease, we critically evaluated the evi-
dentiary basis for an association be-
tween serum mineral levels and car-
diovascular disease and mortality in
individuals with chronic kidney dis-
ease. In particular, we sought to disag-
gregate those studies with more valid
estimates of the association between
mineral levels and outcomes through
adjustment for known confounding
variables.
METHODS
We performed a systematic review and
meta-analysis of cohort studies mea-
suring the association between serum
levels of phosphorus, parathyroid hor-
mone, or calcium and death or cardio-
vascular events in individuals with
chronic kidney disease according to the
Preferred Reporting Items for System-
atic Reviews and Meta-Analyses guide-
lines.15 A specialized librarian con-
ducted a systematic and comprehensive
database search of MEDLINE (1948 to
December 2010) and EMBASE (1947
to December 2010) using a strategy that
combined text word and Medical Sub-
ject Headings without language restric-
tion (eTable 1 at http://www.jama
.com). We also hand-searched the
reference lists of primary studies, re-
view articles, and clinical guidelines. We
inspected the full text of any citation
that appeared relevant.
We extracted data on the character-
istics of study design, participants, ex-
posures, and covariates together with
the outcomes of all-cause mortality, car-
diovascular mortality, and nonfatal
cardiovascular events. Whenever avail-
able, we extracted the number of indi-
viduals at risk, and the adjusted haz-
ard ratio or relative risk (RR) per unit
baseline serum concentrations of phos-
phorus (1 mg/dL), parathyroid hor-
mone (100 pg/mL), or calcium (1 mg/
dL). The standard error of the estimate
was also extracted or estimated from the
reported 95% confidence interval (CI)
if necessary. In addition, we extracted
the adjusted hazard ratio or RR for each
reported category of baseline serum
concentrations of phosphorus, para-
thyroid hormone, or calcium. For each
category of serum level exposure, we
assigned the numerical value for the risk
category as the midpoint of the upper
and lower bound of the reported cat-
egory.16 Whenever the category was
open ended at the upper bound (eg, se-
rum phosphorus 11 mg/dL), the as-
signed value recorded was the lower
bound value of the category (11 mg/
dL). Risk estimates for discrete pa-
tient cohorts reported within the same
study (ie, participants receiving hemo-
dialysis or peritoneal dialysis) were ex-
tracted separately.17,18 Whenever more
than 1 publication reported data, we
used all available reports to inform our
data extraction while taking care to
avoid duplication of information. Risks
of bias in each study were assessed
according to previously published
methods.19
We plotted the reported log RR es-
timate for the outcomes of all-cause
mortality, cardiovascular mortality, or
nonfatal cardiovascular events against
the corresponding category of serum
level of phosphorus, parathyroid hor-
mone, and calcium in each available co-
hort to qualitatively assess the linear-
ity of the associations on the log scale.
We then used the study-specific esti-
mates of the RR per unit increase in se-
rum level to calculate the summary es-
timates of RR (with 95% CI) per unit
of increase in serum level of phospho-
rus, parathyroid hormone, or cal-
cium. When this estimate was not avail-
able for a study, we used the methods
described by Hartemink et al20 to cal-
culate RR estimates per unit of expo-
sure based on the category-specific es-
timates of risk if the required data were
reported. This method assumes that the
relationship between the RR estimate
per unit of exposure (level of serum
phosphorus, parathyroid hormone, or
calcium) is approximately linear.
Using studies where a linear asso-
ciation between log RR and exposure
was reported or was estimable, we fit-
ted a random-effects meta-regression
model using the log RR per unit of ex-
posure as the outcome to obtain a sum-
mary estimate of the log RR. The in-
cremental units assigned were serum
levels of phosphorus per 1-mg/dL in-
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crease relative to a referent value of 3.5
mg/dL (to convert to mmol/L, multi-
ply by 0.323), parathyroid hormone per
100-pg/mL increase relative to a refer-
ent value of 200 pg/mL (to convert to
ng/L, multiply by 1), and calcium per
1-mg/dL increase relative to a referent
serum value of 8.4 mg/dL (to convert
to mmol/L, multiply by 0.25). The
meta-regression took account of the
standard error for the estimate for each
study. The summary log RR was expo-
nentiated to obtain the summary esti-
mate of RR.
We used subgroup analysis and
meta-regression to assess the effect of
adjustment for the key covariates of
age, cardiovascular disease, diabetes
status, time receiving dialysis (or esti-
mated glomerular filtration rate for
individuals not requiring dialysis),
and race or ethnicity. The quality of
adjustment was defined a priori as
adequate when outcomes were
adjusted for all 5 covariates and as
partial when adjusted for 4 or fewer
covariates. We also assessed the RR of
mortality per unit of exposure for
each of the following study-level
covariates (when possible): age, pro-
portion of men, race, stage of chronic
kidney disease (dialysis, transplant,
chronic kidney disease), dialysis
adequacy, date of publication, dura-
tion of study, exposure measurement,
and number of participants.
We conducted sensitivity analyses to
evaluate whether using adjustment for
cardiovascular disease as a criterion for
assessing study quality altered our find-
ings. Also, several studies were de-
rived from the same data sources (eg,
US Renal Data System, Dialysis Out-
comes Practice Patterns Study). When-
ever possible, we conducted sensitiv-
ity analyses by including studies from
the same data source separately in sum-
mary analyses. For all analyses, a
2-tailed P value of less than .05 indi-
cates statistical significance. Analyses
were undertaken using SAS software
version 9.2 (SAS Institute Inc, Cary,
North Carolina) and Stata software ver-
sion 11 (StataCorp, College Station,
Texas) for the meta-regression.
RESULTS
A systematic search yielded 47 eli-
gible studies (N = 327 644) in 49
cohorts of adults with chronic kid-
ney disease (FIGURE 1; eTable 2 at http:
//www.jama.com). The population sizes
of the studies, all published between
1995 and 2010, varied between 99 and
78 420 individuals. The 12 studies that
enrolled more than 5000 individuals
were derived from registry data-
bases.21-32 Study duration ranged be-
Figure 1. Flow Diagram of the Identification Process for Eligible Studies
14 Studies (n = 109 670) included in summary analyses
Serum phosphorus
Mortality: 13 studies (n = 92 345)
Cardiovascular mortality: 3 studies (n = 23 207)
Cardiovascular events: 0 studiesa
Serum parathyroid hormone
Mortality: 4 studies (n = 101 058)
Cardiovascular mortality: 2 studies (n = 22 367)
Cardiovascular events: 0 studiesa
Serum calcium
Mortality: 8 studies (n = 106 156)
Cardiovascular mortality: 2 studies (n = 22 367)
Cardiovascular events: 0 studiesa
47 Studies (56 articles; n = 327 644) included in systematic review
Serum phosphorus
Mortality: 29 studies (n = 307 630)
Cardiovascular mortality: 8 studies (n = 65 463)
Cardiovascular events: 9 studies (n = 77 495)
Serum parathyroid hormone
Mortality: 28 studies (n = 266 925)
Cardiovascular mortality: 10 studies (n = 63 313)
Cardiovascular events: 7 studies (n = 71 548)
Serum calcium
Mortality: 22 studies (n = 254 151)
Cardiovascular mortality: 5 studies (n = 49 810)
Cardiovascular events: 8 studies (n = 72 168)
33 Studies excluded (n = 217 974)
1123 Excluded (duplicate reports)
94 Articles identified for full-text review






16 No exposure to serum phosphorus, parathyroid
hormone, or calcium 
8 Outcome not mortality or nonfatal cardiovascular events
8 Review article, commentary, or editorial
3 Not longitudinal cohort study
2 Ongoing study
1 Not chronic kidney disease population
7163 Articles excluded
2562 No exposure to serum phosphorus, parathyroid
hormone, or calcium 
2009 Not chronic kidney disease population
782 Outcome not mortality or nonfatal cardiovascular events
606 Review article, commentary, or editorial
552 Not longitudinal cohort study
342 Pediatric population
310 Not human population study
aSummary estimate not possible due to insufficient data.
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tween 12 and 360 months. The vast ma-
jority of data were derived from cohorts
requiring dialysis. Twenty-four stud-
ies (51%) assessed outcomes in 310 273
individuals receiving hemodialy-
sis,21-44 and 3 studies assessed out-
comes in 1124 participants receiving
peritoneal dialysis.45-47 Five studies com-
bined analysis in 3233 participants re-
ceiving hemodialysis and peritoneal di-
alysis,48-52 and 2 studies (n = 2251)
analyzed outcomes for separate co-
horts receiving hemodialysis and peri-
toneal dialysis.17,18 One study com-
bined 98 individuals receiving dialysis,
transplant recipients, and those with
chronic kidney disease.53 Four studies
evaluated 1675 kidney transplant
recipients.54-57 Eight studies (n=8990)
included individuals with chronic
kidney disease in stages 3 through
5.58-65
Outcomes were evaluated based on se-
rum exposures at commencement of di-
alysis in 8 cohorts,18,38,41,43,48-51 at the time
of kidney transplantation in 3 co-
horts,55,56,62 and at the onset of chronic
kidney disease in 2 cohorts.63,64 The defi-
nitions and sources of data for all-cause
mortality, cardiovascular mortality, and
cardiovascular events that were re-
ported in the included studies appear in
eTable 3 (at http://www.jama.com). Car-












Adequate adjustment Partial adjustment
Serum parathyroid hormone
Studies
Block et al,21 1998
Slinin et al,30 2005
Young et al,32 2005
Melamed et al,49 2006
Tentori et al,31 2008
Wald et al,44 2008
Dukkipati et al,35 2010
0 200 400 600
Serum Parathyroid Hormone, pg/mL
Studies
Coco and Rush,33 2000
Avram et al,17 2001 (HD)
Avram et al,17 2001 (PD)
Dimkovic et al,46 2002
Guh et al,37 2002
Block et al,22 2004
Stevens et al,52 2004
Noordzij et al,18 2005 (HD)
Noordzij et al,18 2005 (PD)
Osawa et al,50 2005
Dussol et al,36 2007
Kimata et al,25 2007
Komaba et al,39 2008
Kovesdy et al,59 2008
Drechsler et al,34 2009
Fellah et al,53 2009
Morrone et al,41 2009
Smith et al,64 2009
Lacson Jr et al,26 2009
0 400 800 1200


















Adequate adjustment Partial adjustment
Serum calcium
Studies
Block et al,21 1998
Kestenbaum et al,58 2005
Slinin et al,30 2005
Young et al,32 2005
Melamed et al,49 2006
Voormolen et al,65 2007
Tentori et al,31 2008
Wald et al,44 2008
4 6 8 10 12
Serum Calcium, mg/dL
Studies
Stevens et al,52 2004
Noordzij et al,18 2005 (HD)
Noordzij et al,18 2005 (PD)
Osawa et al,50 2005
Egbuna et al,55 2007
Rodriquez-Benot et al,42 2005
Kimata et al,25 2007
Schaeffner et al,57 2007
Komaba et al,39 2008
2 4 6 8 10 12
Serum Calcium, mg/dL




Block et al,21 1998
Saran et al,29 2003
Port et al,27 2004
Kestenbaum et al,58 2005
Slinin et al,30 2005
Young et al,32 2005
Melamed et al,49 2006
Voormolen et al,65 2007
Tentori et al,31 2008
Wald et al,44 2008
Kovesdy et al,60 2010
0 1 2 3 4 5 6 7 8
Serum Phosphorus, mg/dL
Studies Partial adjustment
Jassal et al,38 1996
Coco and Rush,33 2000
Cueto-Manzano et al,45 2001
Block et al,22 2004
Stevens et al,52 2004
Menon et al,61 2005
Noordzij et al,18 2005 (HD)
Noordzij et al,18 2005 (PD)
Osawa et al,50 2005
Rodriguez-Benot et al,42 2005
Kimata et al,25 2007
Schaeffner et al,57 2007
Komaba et al,39 2008
Phelan et al,51 2008
Connolly et al,54 2009

















The data with dashed lines represent the studies graphically displayed that reported relative risk (RR) per unit change in serum phosphorus, parathyroid hormone, or calcium
as continuous and not categorical variables (ie, these studies reported RRper unit change, and their slope is provided in the graphs). Studies are stratified into adequate
adjustment for confounding variables (all 5 covariates: age, race, time receiving dialysis [or estimated glomerular filtration rate], cardiovascular disease, and diabetes mellitus)
or partial adjustment (5 covariates). HD refers to the hemodialysis cohort within the study. PD refers to the peritoneal dialysis cohort within the study.
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diovascular mortality and cardiovascu-
lar events were generally defined as death
or hospitalization due to myocardial in-
farction, atherosclerotic heart disease,
cardiac arrest, or arrhythmia.
By current standards,19 we found that
reporting of study methods was incom-
plete, suggesting risks of bias existed in
the included studies (eFigure 1 at http:
//www.jama.com). Notably, data re-
porting completeness to follow-up
(study attrition) and prognostic factor
measurement were incomplete or un-
clear in approximately 90% of studies.
Sixteen studies (34%) reported on
methods used to adjudicate mortality
events and, of these, 1 study reported
formal adjudication procedures,34 sug-
gesting misclassification bias was pos-
sible in the remainder. Age was ad-
justed for in 46 studies (98%) and
diabetes mellitus (81%), time receiv-
ing dialysis or duration of chronic kid-
ney disease (66%), cardiovascular dis-
ease (47%), and race or ethnicity (47%).
Thirteen studies (28%) reported risks
of mortality or cardiovascular events ac-
cording to the mean of serum levels.*
From these studies, we extracted risks
for outcomes based on the mean of se-
rum levels in the period before study
commencement in 6 studies,22,26,35,40,49,58
mean of serum levels during the en-
tire follow-up in 6 studies,24,33,37,43,48,56
and the mean of serum values in the pe-
riod immediately before death or study
completion in 1 study.42
Of the 47 studies overall, graphical
evaluation of the relationship between
categories of serum exposure and
risk was not possible in 7 studies
(n=74 114) because risk estimates for
levels of serum exposure and an esti-
mate of variance were not reported in
an extractable format or a linear esti-
mate of risk per unit increase in expo-
sure was not extractable.23,24,43,47,56,62,63
Overall, 33 studies (n=217 974) were
not included in the meta-regression
because they did not report the
relationship between log RR per
unit exposure, or this was not esti-









ies with partial adjustment (FIGURE 2;
eFigure 2 and eFigure 3 at http://www
.jama.com). It should be noted that in
general within most of the included
studies, reported RRs derived from a
base multivariate model that usually in-
cluded age, race, sex, diabetes, and kid-
ney function or duration of dialysis were
not substantially altered by adjust-
ment for additional potential confound-
ing variables. Summary estimates for
risks of all-cause mortality, cardiovas-
cular mortality, and nonfatal cardio-
vascular events are shown in FIGURE 3.
In 12 partially adjusted studies (13
cohorts), the risk of death was higher
with increasing levels of serum phos-
phorus (Figure 2).† In 10 adequately
adjusted studies, the relationship
between serum phosphorus and all-
*References 22, 24, 26, 33, 35, 37, 40, 42, 43, 48,
49, 58, 60.
†References 18, 22, 25, 26, 39, 42, 45, 51, 52, 54,
57, 61.
Figure 3. Summary Estimates for Risks of All-Cause Mortality and Cardiovascular Mortality













4651Adequate adjustment 3 1.35 (1.16-1.57)
87 694Partial adjustment 10 1.16 (1.09-1.23)
92 345All studies combined 13 1.18 (1.12-1.25)
Cardiovascular mortality
17 326Adequate adjustment 1 Not estimable
5881Partial adjustment 2 1.14 (1.05-1.24)
23 207All studies combined 3 1.10 (1.06-1.13)
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17 326Adequate adjustment 1 Not estimable
83 732Partial adjustment 3 1.01 (0.99-1.03)
101 058All studies combined 4 1.01 (1.00-1.02)
Cardiovascular mortality
17 326Adequate adjustment 1 Not estimable
5041Partial adjustment 1 Not estimable
22 367All studies combined 2 1.05 (0.99-1.11)













22 367Adequate adjustment 2 1.07 (0.91-1.24)
83 789Partial adjustment 6 1.09 (0.99-1.20)
106 156All studies combined 8 1.08 (1.00-1.16)
Cardiovascular mortality
17 326Adequate adjustment 1 Not estimable
5041Partial adjustment 1 Not estimable
22 367All studies combined 2 1.15 (1.08-1.23)
Relative Risk (95% CI)
Risks of all-cause mortality, cardiovascular mortality, and nonfatal cardiovascular events are shown per 1-mg/dL
increase in serum levels of phosphorus, 100-pg/mL increase in serum parathyroid hormone, and 1-mg/dL in-
crease in serum calcium. Summary estimates are not reported when only a single cohort contributed data. CI
indicates confidence interval.
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cause mortality was more consistent
and an increasing risk of death was
apparent at higher levels of serum
phosphorus (5.5 mg/dL). Based on
studies reporting a continuous RR for
each 1-mg/dL increase in serum phos-
phorus25,26,33,38,40,42,50,52,58,60,61,65 together
with a study in which the RR was esti-
mated from reported event data,57 we
found that for every 1-mg/dL increase
in serum phosphorus, the risk of mor-
tality increased by 35% (RR, 1.35; 95%
CI, 1.16-1.57) in the 3 adequately
adjusted studies58,60,65 and by 18% (RR,
1.18; 95% CI, 1.12-1.25) in the 13
available studies overall. We could not
include the study by Young et al32 in
these analyses because there was
strong indication of nonlinearity based
on reported risks for categories of
serum phosphorus (Figure 3). How-
ever, addition of this study using the
reported RR per unit increase in serum
phosphorus made a negligible differ-
ence to the summary estimates. Only a
single study with adequate adjust-
ment for confounders reported the
association between serum level of
phosphorus and risk of cardiovascular
mortality32; however, in the 3 studies
reporting this outcome overall, the
risk of cardiovascular mortality
increased by 10% per 1-mg/dL
increase in serum phosphorus (RR,
1.10; 95% CI, 1.06-1.13).25,32,61 No
data were available for the association
between serum phosphorus and non-
fatal cardiovascular events.
Whereas on visual inspection, 17 par-
tially adjusted studies (19 cohorts)
tended to show an increased risk of all-
cause mortality at lower serum levels
of parathyroid hormone (Figure 2),‡ a
summary analysis of the 4 available
studies25,26,32,50 found no relationship be-
tween parathyroid hormone and all-
cause mortality (Figure 3). Only a single
adequately adjusted study reported the
association between parathyroid hor-
mone and cardiovascular mortality31
and no data were available for nonfa-
tal cardiovascular events30 in a format
extractable for analysis; therefore, sum-
mary estimates for these risks were not
calculated. However, when we com-
bined the adequately and partially ad-
justed studies, we found no evidence
for association between parathyroid
hormone and cardiovascular mortal-
ity (Figure 3).
No association between all-cause
mortality and serum calcium levels was
observed in 2 adequately adjusted stud-
ies (Figure 3).30-32,44,49 Only a single ad-
equately adjusted study provided data
for the association between serum cal-
cium levels and risks of cardiovascu-
lar mortality32 and no data were avail-
able for nonfatal cardiovascular events.30
However, in all studies combined, there
was evidence of association between se-
rum calcium level and cardiovascular
death18,31 (RR, 1.15; 95% CI, 1.08-
1.23) (Figure 3).30,48
We performed univariate meta-
regression to identify other factors that
might predict a relationship between se-
rum level of phosphorus (eFigure 4 at
http://www.jama.com) or calcium
(eFigure 5) and risks of all-cause mor-
tality. Univariate meta-regression was
not possible for serum level of para-
thyroid hormone because fewer than 5
studies were available for the analy-
ses. Risks of all-cause mortality asso-
ciated with serum phosphorus and cal-
cium were similar across different stages
of chronic kidney disease. In the 4 stud-
ies58,60,61,65 reporting outcomes for in-
dividuals with chronic kidney disease
not yet requiring dialysis, the risk of all-
cause mortality for each 1-mg/dL in-
crease in serum level of phosphorus
(RR, 1.29; 95% CI, 1.12-1.48) was
similar to that observed in 8 stud-
ies25,26,33,38,40,42,50,52 of individuals requir-
ing dialysis (RR, 1.17 [95% CI, 1.08-
1.25]; P = .22). No evidence of an
association between serum calcium and
all-cause mortality was found in either
individuals with earlier stages of chronic
kidney disease (RR, 1.02; 95% CI,
0.81-1.29)32,58 or those requiring dialy-
sis (RR, 1.09 [95% CI, 1.00-1.18];
P=.63).25,26,32,42,50,52,57
We assessed the robustness of our as-
sumption that adjusting for cardiovas-
cular disease was necessary to define a
study as adequately adjusted (in addi-
tion to age, race, duration of dialysis or
kidney function, and presence of dia-
betes mellitus). When excluding car-
diovascular disease as a criterion for ad-
justment quality, 6 studies (7 cohorts)
were adjudicated as adequately ad-
justed.17,22,24,26,52,60 Of these, 2 stud-
ies26,52 contributed data to the sum-
mary analysis for phosphorus and
all-cause mortality. Categorizing these
studies as adequately adjusted in the
meta-analysis for this outcome did not
alter the association we found be-
tween serum level of phosphorus and
death (RR, 1.24; 95% CI, 1.12-1.37).
These 2 studies were also in the meta-
analysis for calcium and all-cause mor-
tality. Adjudication of these studies as
adequate did not meaningfully alter the
summary estimate we found for the as-
sociation between serum level of cal-
cium and all-cause mortality (RR, 1.09;
95% CI, 0.98-1.21).
Several studies were derived from the
same source; 4 studies were derived
from the US Renal Data System21,23,28,30
and 5 studies included individuals
sourced from the Dialysis Outcomes
and Practice Patterns Study.25,27,29,31,32 Of
all the meta-analyses, 2 studies from the
same data source contributed to the
summary estimates for parathyroid hor-
mone and calcium and all-cause mor-
tality. Entering these 2 studies25,32 sepa-
rately into the meta-analyses for all
studies combined and only for ad-
equately adjusted studies did not mean-
ingfully change the associations we ob-
served between serum parathyroid
hormone and serum calcium with all-
cause mortality.
COMMENT
When receiving treatment designed to
reach proposed serum target levels for
phosphorus, parathyroid hormone, and
calcium, individuals with chronic kid-
ney disease, clinicians, and policy mak-
ers need to know whether serum lev-
els have any evidence of association
with health outcomes. Prior treat-
ment trials for mineral and bone dis-
order in chronic kidney disease found
‡References 17, 18, 22, 25, 33, 34, 36, 37, 39, 41,
46, 52, 53, 59, 64.
MINERAL TARGETS IN CHRONIC KIDNEY DISEASE
1124 JAMA, March 16, 2011—Vol 305, No. 11 (Reprinted) ©2011 American Medical Association. All rights reserved.
no evidence for clinical benefit for any
of the agents tested so far.11-13 Our study
provides the first systematic and criti-
cal review using data from cohort stud-
ies of the association between serum
levels of phosphorus, parathyroid hor-
mone, and calcium and death and car-
diovascular outcomes in individuals
with chronic kidney disease.
Overall, we were unable to demon-
strate any strong or consistent associa-
tion between death and serum levels of
parathyroid hormone and calcium in in-
dividuals with chronic kidney dis-
ease. While there may be an associa-
tion between death and higher serum
levels of phosphorus irrespective of the
stage of kidney disease, high-quality
data for an association between serum
levels of phosphorus, parathyroid hor-
mone, and calcium with cardiovascu-
lar mortality were available only in
single cohort studies and summary es-
timates for cardiovascular events were
not available. Consequently, based on
the available cohort data and the ab-
sence of randomized controlled trials,
the evidentiary basis for current clini-
cal guideline–recommended targets of
serum phosphorus, parathyroid hor-
mone, and calcium in chronic kidney
disease is poor.9,10
Broad adoption of health care prac-
tices that have insufficient evidence for
safety or efficacy (in this case target-
ing serum mineral levels in individu-
als with chronic kidney disease) may
lead to considerable unintended harm.
Examples in medicine include the
widespread adoption of treatment using
encainide and flecainide to suppress
ventricular tachyarrhythmias after myo-
cardial ischemia and hormone therapy
in postmenopausal women to prevent
cardiovascular disease until random-
ized trials unequivocally demon-
strated such interventions were harm-
ful.66,67
We now demonstrate that the evi-
dence is similarly lacking for serum
mineral target levels as risk factors for
poor health outcomes in individuals
with chronic kidney disease despite
nearly universal adoption of such tar-
gets in the field of nephrology.68,69 The
current data do not support the hy-
pothesis that individuals with chronic
kidney disease should have treatment
to achieve targeted levels of serum para-
thyroid hormone or calcium to reduce
mortality or cardiovascular morbid-
ity, except at extreme levels in which
hypocalcemia and hypercalcemia re-
sult in immediate, clinically apparent
adverse events such as tetany and sei-
zures. Furthermore, treating high phos-
phorus levels is linked to a substantial
pill burden that is associated with lower
quality of life in individuals with
chronic kidney disease.70 While we do
not conclude that normalizing serum
levels of calcium or phosphorus or
avoiding upper or lower extremes of se-
rum level of parathyroid hormone is fu-
tile, high-quality evidence is required
before specific treatment should be ad-
vocated strongly.
Accumulating cohort data demon-
strate that associations exist between
vitamin D and phosphorus binder treat-
ment and lower mortality and cardio-
vascular events in individuals with
chronic kidney disease that may be in-
dependent of their treatment effects on
serum levels of phosphorus and para-
thyroid hormone.71-74 Vitamin D recep-
tor activation may attenuate left ven-
tricle structural abnormalities, reduce
left ventricle mass, and improve dia-
stolic function.75 Given the associa-
tions between phosphorus level and car-
diovascular events we found in the
current study together with these un-
controlled data suggesting benefit for
specific interventions in chronic kid-
ney disease, we strongly advocate that
large simple placebo-controlled ran-
domized trials be conducted of vita-
min D, calcimimetic agents (allosteric
modulators of parathyroid calcium–
sensing receptors that lower parathy-
roid hormone secretion), or phospho-
rus binders in individuals with chronic
kidney disease.
The earlier focus by the nephrology
community on hemoglobin targets
is a relevant cautionary tale. Because
hemoglobin targets became the re-
search priority, there was consider-
able delay in commencing a large pla-
cebo-controlled trial for anemia in
individuals with chronic kidney dis-
ease. Similarly, the limited evidentiary
basis for an association between se-
rum mineral levels and health out-
comes in the present analysis suggests
that target trials of serum levels of phos-
phorus, parathyroid hormone, and cal-
cium should not be promoted in indi-
viduals with chronic kidney disease.76
Our study has limitations that should
be considered. First, our conclusions are
supported by low-quality data be-
cause summary effects are derived from
uncontrolled cohort studies that are vul-
nerable to the unpredictable confound-
ing effects of measured and unmea-
sured variables. Notably, within most
of the included studies, RRs from a ba-
sic adjusted model were not altered by
further adjustment for additional vari-
ables, indicating that partial adjust-
ment was not an important limitation
of these studies.
Second, we have assumed that the
relationship between serum levels of
phosphorus, parathyroid hormone,
and calcium and health outcomes is
approximately linear. While we
assessed the validity of this assump-
tion in individual studies using a
regression analysis, the small number
of exposure categories within most of
the studies meant that we had limited
power to detect nonlinear relation-
ships between serum levels and log
risks of mortality. Third, we have not
assessed study data for the association
between serum levels of alkaline
phosphatase or vitamin D levels and
mortality, which are both emerging as
predictors of outcomes in populations
with and without chronic kidney dis-
ease in cohort studies77-79 and are
potential effect modifiers of the rela-
tionships between serum targets and
outcomes that we have observed. We
also have not studied the effects of
serum mineral levels on other rel-
evant clinical outcomes such as mus-
culoskeletal pain or itch. Finally,
phosphorus and calcium may func-
tion poorly as biomarkers because
they represent only a fraction of body
stores and have substantial intraindi-
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vidual variability over time (despite
assay precision).
In conclusion, the evidence for an as-
sociation between serum levels of phos-
phorus, calcium, or parathyroid hor-
mone as risk factors for outcomes in
individuals with chronic kidney dis-
ease (at any stage) is currently insuffi-
cient to inform clinical decision mak-
ing, policy, or practice guidelines. Large
placebo-controlled randomized trials of
vitamin D compounds, phosphorus
binders, and calcimimetic agents are
now needed to evaluate whether treat-
ing mineral disorders improves health
outcomes for individuals with chronic
kidney disease.
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